Nivolumab potentially superior to standard chemo in advanced melanoma

Targeted therapy for iodine-refractory thyroid cancer

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib

Combining cobimetinib and vemurafenib improves progression-free survival in advanced melanoma

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Cediranib and chemo combo improves PFS for metastatic cervical cancer

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

New drug anamorelin shows improvement in appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

Optimising metastic renal cell carcinoma (mRCC): Treatment lessons from the real world: Introduction